Navigation Links
Researchers report new autism genes discovered
Date:6/9/2010

University of Illinois at Chicago researchers are part of an international consortium working with Autism Speaks, the world's largest autism science and advocacy organization, which today reports new autism genetic discoveries.

The results, from the second phase of the collaborative Autism Genome Project, are published in the June 10 issue of the journal Nature.

Autism is a complex neurobiological disorder that inhibits a person's ability to communicate and develop social relationships, and is often accompanied by behavioral challenges. Autism spectrum disorders are diagnosed in one in 110 children in the U.S., affecting four times as many boys as girls.

The new report shows that individuals with autism tend to carry more sub-microscopic insertions and deletions called copy-number variants (CNV) in their genome than nonautistic people do. Some of these CNV appeared to be inherited, while others are considered new because they are found only in affected offspring and not in the parents. Taken together, more of the CNVs disrupt genes previously reported to be implicated in intellectual disability without autism or in autism than expected by chance.

The findings are based on analysis of high-density genotyping data collected from 1,000 individuals with autism spectrum disorder (ASD) and 1,300 without ASD.

The new study also identified new autism susceptibility genes including SHANK2, SYNGAP1, DLGAP2 and the X-linked DDX53PTCHD1 locus. Some of these genes belong to synapse-related pathways, while others are involved in cellular proliferation, projection and motility, and intracellular signaling, functional targets that may lead to the development of new treatment approaches.

These findings further support an emerging consensus within the scientific community that autism is caused in part by many "rare variants" or genetic changes found in less than 1 percent of the population. While each of these variants may only account for a small fraction of the cases, collectively they are starting to account for a greater percentage of individuals in the autism community, as well as providing insights into possible common pathogenic mechanisms.

The overlap between autism susceptibility genes and genes previously implicated in intellectual disabilities further supports the hypothesis that at least some genetic risk factors are shared by different psychiatric developmental disabilities. The identification of these biological pathways points to new avenues of scientific investigation, as well as potential targets for the development of novel treatments, according to the authors.

"These results are another step on the long path to sufficiently understanding autism to further develop treatments for the core symptoms of autism," says Dr. Edwin Cook, UIC professor of psychiatry.

"At the Autism Center of Excellence at UIC, we continue to work to understand the genetics, neurobiology, and treatment of autism," he said.


'/>"/>

Contact: Sherri McGinnis Gonzlez
smcginn@uic.edu
312-996-8277
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. Simple eye test measures damage from multiple sclerosis, UT Southwestern researchers find
2. B2Discovery: Entrepreneurs and researchers join forces to conquer cancer
3. Researchers Report Treatment Headway Against Lung Cancer
4. MSU researchers discover potential genetic factor in eating disorders
5. Mount Sinai researchers approaching universal treatment for all strains of influenza
6. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
7. Basque researchers apply chemistry to restoration of paintings and dating of signatures
8. Researchers offer solutions to poisonous well-water crisis in southern Asia
9. Researchers report no difference in breast cancer characteristics after oophorectomy
10. Vanderbilt researchers play major role in new center on electronic health information privacy
11. Pitt researchers discover gene mutation linked to lymphatic dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... D.C. (PRWEB) , ... June 24, 2016 , ... ... Heroes Golf Classic Tournament held on June 20th at the Woodmont Country Club ... charity, Luke’s Wings, an organization dedicated to helping service members that have been wounded ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... management skills and infrastructure. Most providers, however, are unsure how to move forward, ... Ascend to define a path forward tailored to an organization’s specific needs. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: